InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.63
(
-0.08%
)
Bitcoin
60,323.41
(
2.23%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 18
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: pcrutch post# 126486

Tuesday, 09/13/2011 11:11:08 AM

Tuesday, September 13, 2011 11:11:08 AM

Post# of 252939
Also from GSK/LGND

LB-3. Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated With Thrombocytopenia. N. Afdhal; G. Dusheiko; E. G. Giannini; P. Chen; K. Han; A. Moshin; M. Rodriguez-Torres; S. Rugina; E. Lawitz; M. L. Shiffman; G. Tayyab; F. Poordad; Y. Mostafa Kamel; A. Brainsky; J. Geib; S. Y. Vasey; R. Patwardhan; F. M. Campbell; D. Theodore

Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up